Close

Roth Capital Downgrades IRadimed Corp (IRMD) to Neutral

Go back to Roth Capital Downgrades IRadimed Corp (IRMD) to Neutral

Iradimed Corp. (IRMD) Cuts Q3, FY16 Outlook

October 4, 2016 6:56 AM EDT

Iradimed Corp. (Nasdaq: IRMD) revised its third quarter and full year 2016 financial guidance.

The Company now expects revenue for the third quarter 2016 of approximately $7.5 million to $7.6 million, compared to its previous guidance of $9.9 million to $10.0 million and GAAP diluted earnings per share of approximately $0.09 to $0.10. The Company also now expects non-GAAP diluted earnings per share of approximately $0.11 to $0.12, compared to its previous guidance of $0.23 to $0.24.

For the full year 2016, the Company now expects revenue of approximately $32.9 million to $33.2 million, compared to its previous guidance of $39.0 million to $40.0 million and GAAP diluted earnings per... More